Omidenepag
# Omidenepag

Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.

Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022.

## Medical uses

Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.

## Adverse effects

The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.

## Pharmacology

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. Omidenepag is a selective prostaglandin E2 receptor agonist.

## History

Omidenepag was developed by Ube Industries and Santen Pharmaceutical.

